Abstract: Needle-stick injuries are associated with considerable risk of morbidity for healthcare workers and patients. The present invention of a handheld surgical suturing device allows for visualization of surgical field and better control of the suture needle with possible one-hand operation The device also provides active safety features that protect the surgeon from needle-stick injury.
Abstract: Disclosed are methods for diagnosing AMD or a susceptibility for AMD by identifying one or more markers associated with peripheral retinal phenotypes.
Type:
Application
Filed:
April 27, 2009
Publication date:
December 1, 2011
Applicants:
THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC.
Abstract: The present invention relates to systems, compositions, and methods for using bone mineral density ratios as a predictor of osteoarthritis. In particular, the present invention relates to comparing ratios of bone mineral density involving bones that are periarticular to determine a risk assessment for features of osteoarthritis.
Abstract: A system, method, and computer program product of clinical treatment planning implements complex Monte Carlo (MC) based brachytherapy dose distributions using conventional brachytherapy treatment planning systems (TPS). Dose distributions from complex brachytherapy source configurations determined with MC methods are used as inputs. Radial dose functions and 2D anisotropy functions are obtained by positioning the coordinate system origin along the dose distribution cylindrical axis of symmetry. Origin to tissue distance and active length are chosen to minimize TPS interpolation errors. A 2D anisotropy function is determined, and a brachytherapy dose rate constant is selected. A virtual brachytherapy source dose distribution is calculated based upon the complex treatment configuration. Additional dosimetry parameters may be considered as well, and dose distributions may be calculated and compared to the original MC-derived dose distributions.
Abstract: The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors.
Type:
Application
Filed:
April 17, 2009
Publication date:
July 21, 2011
Applicant:
Tufts Medical Center, Inc., (f/k/a/ New England Medical Center Hospitals, Inc.)
Abstract: A method for fetal monitoring includes acquiring electrical signals from a set of electrodes, for example, a set of surface electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including by performing a morphological analysis of fetal electrocardiogram signals. A clinical indicator is then determined from a result of performing the morphological analysis.
Type:
Grant
Filed:
April 15, 2009
Date of Patent:
May 24, 2011
Assignees:
Tufts Medical Center, Inc., Massachusetts Institute of Technology, E-Trolz, Inc.
Inventors:
Adam J. Wolfberg, Gari D. Clifford, Jay Ward
Abstract: The present invention features a method of diagnosing blood vessel reocclusion in a subject by detecting increased levels of sFLT-1 in a biological sample from the subject.
Type:
Application
Filed:
June 9, 2010
Publication date:
December 23, 2010
Applicant:
Tufts Medical Center, Inc.
Inventors:
Navin K. Kapur, Richard H. Karas, Michael Mendelsohn
Abstract: The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.
Type:
Application
Filed:
June 10, 2010
Publication date:
December 16, 2010
Applicants:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, TUFTS MEDICAL CENTER
Abstract: Methods of reducing and/or protecting against disorders in perinatal subjects are disclosed. Such methods can be used for disorders associated with neuronal cell damage. In certain aspects, the method comprises administering a therapeutically effective amount of neuregulin or a biologically active analog with a pharmaceutical carrier to a perinatal subject. In addition, the perinatal subject can be a fetus where the neuregulin is administered to the pregnant mother. Methods for assessing whether a perinatal subject is at risk for developing a neurological disorder are also disclosed. For example, expression levels of neuregulin can be used as an indication the perinatal subject is at risk for developing a disorder associated with neuronal cell damage. Evaluating the genotype of the NRG locus in a perinatal subject can also be used as an indicator of the risk of developing neurological disorders.
Abstract: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
Abstract: Methods for screening compounds to treat an oncological disorder regulated through a tumor-inducing pathway are provided. The compounds are administered to non-human animal subjects having a disease model, so that the subjects display pathology symptoms that correspond to the oncological disorder in humans. The subjects carry a regulatable transgene expression, of which is associated with tumor formation, and further carry regulatable genes for suppression of tumor formation. The disease-pathology symptoms are induced using a site-specific recombination system to induce expression of the transgene associated with tumor formation and negatively regulate or eliminate the genes for suppression of the tumor formation. The methods further involve analyzing tumor formation in subjects administered the compound and comparing appearance and amount of tumors in the subjects administered the compound with control subjects not administered the compound.
Abstract: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.
Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
Abstract: A chest wall protector comprises a shell made of a relatively hard, rigid material, a cushion attached to the shell such that the cushion is disposed between the shell and a thoracic wall of a person outside of a region over a heart of the person when the protector is worn by the person, and a garment configured to be worn by the person and to retain the shell and cushion in positions to protect a portion of the thoracic wall of the person when the garment is worn by the person.
Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.